O'Gorman, A., Suvitaival, T., Ahonen, L., Cannon, M., Zammit, S., Lewis, G., ... Cotter, D. R. (2017). Identification of a plasma signature of psychotic disorder in children and adolescents from the Avon Longitudinal Study of Parents and Children (ALSPAC) cohort. *Translational Psychiatry, 7*(9), [e1240]. https://doi.org/10.1038/tp.2017.211
The identification of an early biomarker of psychotic disorder is important as early treatment is associated with improved patient outcome. Metabolomic and lipidomic approaches in combination with multivariate statistical analysis were applied to identify plasma alterations in children (age 11) (38 cases vs 67 controls) and adolescents (age 18) (36 cases vs 117 controls) preceding or coincident with the development of psychotic disorder (PD) at age 18 in the Avon Longitudinal Study of Parents and Children (ALSPAC). Overall, 179 lipids were identified at age 11, with 32 found to be significantly altered between the control and PD groups. Following correction for multiple comparisons, 8 of these lipids remained significant (lyosphatididlycholines (LPCs) LPC(18:1), LPC(18:2), LPC(20:3); phosphatididycolines (PCs) PC(32:2; PC(34:2), PC(36:4), PC(0-34-3) and sphingomyelin (SM) SM(d18:1/24:0)), all of which were elevated in the PD group. At age 18, 23 lipids were significantly different between the control and PD groups, although none remained significant following correction for multiple comparisons. In conclusion, the findings indicate that the lipidome is altered in the blood during childhood, long before the development of psychotic disorder. LPCs in particular are elevated in those who develop PD, indicating inflammatory abnormalities and altered phospholipid metabolism. These findings were not found at age 18, suggesting there may be ongoing alterations in the pathophysiological processes from prodrome to onset of PD.

Translational Psychiatry (2017) 7, e1240; doi:10.1038/tp.2017.211; published online 26 September 2017

INTRODUCTION

Psychotic disorders (PD) are among the most severe and debilitating medical diseases, with schizophrenia being the most common, affecting ~ 0.5–1% of the global population.1 At present, the diagnosis of PD is subjective and there are no reliable biological diagnostic tests.2 Over the last decade, the psychosis field of research has shifted its focus to the prodrome or ‘at-risk mental state’ (‘ARMS’) in an attempt to identify and treat subjects at high risk of developing a psychotic illness. Investigations have indicated that 20–30% of these individuals will go on to develop schizophrenia over a 2–3 year period.3 Strong evidence supports early intervention as a means to alleviate and improve therapeutic outcome for individuals.4,5 Owing to the multifactorial complexity of PD,2,6 the identification of a disease signature and molecular biomarker(s) sensitive to the underlying pathogenic factors would be of great importance to assist in early detection and diagnosis7 but also to understand the mechanisms underlying the disease process, which has yet to be fully elucidated.8

Metabolomics, the global study of metabolites in cells, tissues or biofluids has emerged in recent years as a promising tool to identify abnormalities in psychotic illnesses. Metabolomic studies in schizophrenia and related psychoses have highlighted a number of metabolic perturbations such as glucoregulatory processes,9,10 fatty acid and lipid metabolism,11–13 mitochondrial function,14 and proline7 and tryptophan metabolism.15 Although a comprehensive mapping of disturbances in metabolic pathways in PD is still a long way off,16 the most consistent findings involve pathways common to fatty acids and the pro-oxidant/antioxidant balance.17 A recent study by Rice and colleagues reported decreased levels of erythrocyte polyunsaturated fatty acid (PUFA) levels in young people at ultra-high risk of PD,18 providing additional evidence of the putative ω–3 PUFA deficiency syndrome. These studies have identified various metabolite signatures and have contributed to a developing and enhanced understanding of the disease mechanism. However, they generally focus on the adult population who have already transitioned to schizophrenia, with a majority being medicated, and so they are limited in terms of identifying early biomarker signatures of the disease.

The aim of this study was to apply metabolomic approaches to identify plasma alterations in children (age 11) and adolescents

1Department of Psychiatry, Royal College of Surgeons in Ireland (RCSI), Beaumont Hospital, Dublin, Ireland; 2Institute of Food and Health, UCD School of Agriculture and Food Science, University College Dublin (UCD), Belfield, Dublin, Ireland; 3Steno Diabetes Center, Gentofte, Denmark; 4MRC Centre for Neuropsychiatric Genetics and Genomics, Cardiff University, Cardiff, UK; 5Centre for Academic Mental Health, School of Social & Community Medicine, University of Bristol, Bristol, UK; 6Division of Psychiatry, University College London, London, UK; 7Nutrigenomics Research Group, UCD Conway Institute/UCD Institute of Food & Health, School of Public Health, Physiotherapy & Sports Science, University College Dublin (UCD), Belfield, Dublin, Ireland; 8Department of Chemistry, Örebro University, Örebro, Sweden; 9Turku Centre for Biotechnology, University of Turku and Åbo Akademi University, Turku, Finland and 10School of Medical Sciences, Örebro University, Örebro, Sweden. Correspondence: Professor L Brennan, Institute of Food and Health, UCD School of Agriculture and Food Science, University College Dublin (UCD), Belfield, Dublin 4, Ireland. E-mail: lorraine.brennan@ucd.ie or Professor DR Cotter, Department of Psychiatry, Royal College of Surgeons in Ireland (RCSI), Beaumont Hospital, Dublin 9, Ireland. E-mail: david.cotter@rcsi.ie
11These authors contributed equally to this study.
Received 3 March 2017; revised 2 August 2017; accepted 17 August 2017
Global lipidomic analysis

The plasma samples were analysed for global profiling of lipids using a method developed specifically for lipidomics analyses. The samples were prepared following the previously published Folch procedure with minor modifications. Briefly, 10 μl of 0.9% NaCl, 100 μl of CHCl₃:MeOH (2:1, v/v) and 20 μl of a 3.5 μg ml⁻¹ working standard solution of chosen lipid standards (for quality control and data normalisation purposes) were added to 10 μl of each plasma sample. The standard solution contained the following compounds: 1,2-dihetadecanoyl-sn-glycero-3-phosphoethanolamine (PE(17:0/17:0)), N-heptadecanoyl-o-erythro-sphingosylphosphorylcholine (SM(d18:1/17:0)), N-heptadecanoyl-o-erythro-sphingosine (Cer(d18:1/17:0), 1,2-dihetadecanoyl-sn-glycero-3-phosphocholine (PC(17:0/17:0)), 1-heptadecanoyl-2-hydroxy-sn-glycero-3-phosphocholine (LPC(17:0))) and 1-palmitoyl-d31-2-oleoyl-sn-glycero-3-phosphocholine (PC(16:0/d31:18:1))). These were purchased from Avanti Polar Lipids (Alabaster, AL, USA). In addition, 1,2-dimyristoyl-sn-glycero-3-phosphocholine (d14:0/14:0) was purchased from Sigma Aldrich (Wicklow, Ireland) and Tripalmitin-d31-1-1-3C3 (TG(16:0/16:0/16:0)-13C3) and Triocanoin-1,1,1-3C3 (TG(16:0/16:0/16:0)-13C3) from Lardon (Solna, Sweden) for the same purpose. The samples were vortex mixed and allowed to stand on ice for 30 min after which they were centrifuged (9400 g, 3 min, 4 °C). Overall, 60 μl from the lower layer of each sample was then transferred to a glass vial with an insert and 60 μl of CHCl₃:MeOH (2:1, v/v) was added. The samples were then stored at −80 °C until analysis.

Calibration curves (at concentration levels of 100, 500, 1000, 1500, 2000 and 2500 ng ml⁻¹) for quantification of lipids were prepared using 1-hexadecyl-2-(9Z-octadecenoxy)-sn-glycero-3-phosphocholine (PC(16:0/18:1(9Z))), 1-(1Z-octadecenoyl)-2-(9Z-octadecenoxy)-sn-glycero-3-phosphocholine (PC(18:0/18:1(9Z))), 1-octadecanoyl-sn-glycero-3-phosphocholine (LPC(16:0)), 1-(1Z-octadecenoyl)-2-docosahexaenoyl-sn-glycero-3-phosphocholine (PC(18:0/22:6)), 1-stearoyl-2-arachidonoyl-sn-glycero-3-phosphohinositol (Pi(18:0/20:4)) and 1-stearoyl-2-linoleoyl-sn-glycero-3-phosphorylcholine (DG(18:0/20:4)) from Avanti Polar Lipids, 1-Palmitoyl-2-Hydroxy-sn-Glycero-3-Phosphati-dylcholine (LPC(16:0)) from Lardon, and 1,2,3-Trihetadecanoylglycerol (TG(17:0/17:0/17:0)) and 3β-hydroxy-5-cholestene-3-3-lineolate (ChoE(18:2)) from Sigma Aldrich.

The samples were analysed using an ultra-high-performance liquid chromatography quadrupole time-of-flight mass spectrometry method (UHPLC-Q-TOF-MS). The UHPLC system was a 1290 Infinity system from Agilent Technologies (Santa Clara, CA, USA), which was equipped with a multisampler (maintained at 10 °C) using 10% DCM in MeOH and ACN: MeOH:IPA:H₂O (1:1:1:1, v/v/v/v)+0.01% HCOOH as needle wash solutions after each injection for 7.5 s each, a quaternary solvent manager and a column thermostat (maintained at 50 °C). Separations were performed on an ACQUITY UPLC BEH C18 column (2.1 mm × 100 mm, particle size 1.7 μm) by Waters (Milford, CT, USA). The flow rate was 0.4 ml min⁻¹ and the injection volume was 1 μl. H₂O+1% NH₄Ac (1M)+0.1% HCOOH (A) and ACN:IPA (1:1, v/v)+1% NH₄Ac+0.1% HCOOH (B) were used as the mobile phases for the gradient elution. The gradient was as follows: from 0 to 2 min 35–80% B, from 2 to 7 min 80–100% B and from 7 to 14 min 100% B. Each run was followed by a 7 min re-equilibration period under initial conditions (35% B). The mass spectrometer was a 6550 Q-TOF instrument from Agilent Technologies (Agilent) interfaced with a dual jet stream electrospray (dual ESI) ion source. Nitrogen generated by a nitrogen generator (PEAK Scientific, Renfrewshire, Scotland, UK) was used as the nebulising gas at a pressure of 21 psi, as the drying gas at a flow rate of 141 ml min⁻¹ (at 193 °C) and as the sheath gas at a flow rate of 111 ml min⁻¹ (at 379 °C). Pure nitrogen (6.0) from Praxair (Fredericia, Denmark) was used as the collision gas. The capillary voltage and the nozzle voltage were kept at 3643 and 1500 V, respectively. The reference mass solution including ions at m/z 121.0509 and 922.0098 was prepared according to instructions by Agilent and it was introduced to the mass spectrometer through the
other nebuliser in the dual ESI ion source using a separate Agilent series 1290 isocratic pump at a constant flow rate of 4 ml min$^{-1}$ (split to 1:100 before the nebuliser). The acquisition mass range was m/z 100–1700 and the instrument was run using the extended dynamic range with an approximate resolution of 30 000 FWHM measured at m/z 1521.9715 (which is included in the tune mixture) during calibration of the instrument. MassHunters B.06.01 (Agilent) software was used for all data acquisition. Quality control was performed throughout the dataset by including blanks, pure standard samples, extracted standard samples and control plasma samples. Relative standard deviations (%RSDs) for retention times were within accepted analytical limits at averages of 17.5 and 16.6% for the plasma samples and for the pure standard samples, respectively. This shows that the method is reliable and repeatable throughout the sample set.

Lipidomic data were pre-processed with MZmine 2 and peaks were identified based on the internal peak library. Peak areas were normalised by lipid class-specific internal standards and quantified with R based on the inverse-weighted linear model. Internal standard peaks were detected in a targeted way from the standards runs. The internal MS library’s retention times were corrected with R to match the study with a linear correction based on the observed retention times in the standards runs. Other peaks in the sample runs were processed in a non-targeted way as: import of the mzML files, mass detection, chromatogram builder, chromatogram deconvolution, isotopic peak groupers, peak filter, peak list row filter, join aligner, peak list row filter, gap filling, peak list filter, identification with custom data base search. The peak table was filtered in R, allowing the peak to be missing in each of the eight batches in a maximum 50% of the samples. Remaining missing values were imputed with feature-wise half-the-minimum. All lipid metabolites, that were present (non-zero value) in more than 75% of samples were included in the data analyses.

Global metabolomic analysis
Polar metabolites were analysed in the plasma samples using comprehensive two-dimensional gas chromatography combined with time-of-flight mass spectrometry (GC×GC-TOFMS, a LECO Pegasus 2 equipped with a cryogenic modulator from LECO, St. Joseph, MI, USA). Specifically, 400 μl methanol and 10 μl internal standard mixture heptadecanoic acid (175 mg l$^{-1}$), α-valine-d8 (36 mg l$^{-1}$), succinic acid-d4 (59 mg l$^{-1}$) and α-glutamic acid-d5 (110 mg l$^{-1}$) were added to 30 μl of plasma samples. The samples were vortexed and centrifuged for 5 min at 10 000 rpm and half of the supernatant was evaporated to dryness. This was followed by two-step methylation and silylation. Specifically, the samples were derivatised by adding first 25 μl methoxamine MOX (45 °C, 60 min) and then 25 μl N-trimethylsilyl-N-methyl trifluoroacetamide MSTFA (45 °C, 60 min). Finally, 50 μl of a retention index standard mixture (n-alkanes, c8–c24, 8 mg l$^{-1}$) with an injection standard (4,4′-dibromooctfluorobiphenyl, c10 10 mg l$^{-1}$), both in hexane, was added to the mixture. The calibration consisted of six points for each quantified metabolite. The columns were as follows: a methyl deactivated retention gap (1.5 m x 0.53 mm i.d.) was connected to 10 m x 0.18 mm Rtx-5 (i.d. diameter 0.18 mm, df$_{phase}$ thickness 0.20 μm) and to 1.5 m x 0.1 mm BPX-50 (i.d. 0.1 mm, df$_{phase}$ thickness 0.1 μm). Helium was used as the carrier gas at a constant pressure mode (40psi). A 4 s separation time was used in the second dimension. The temperature programme was as follows for the first-dimension column: 50 °C (2 min), at 7 °C min$^{-1}$ to 240 °C and at 25 °C min$^{-1}$ to 300 °C (3 min). The second-dimension column temperature was 15 °C higher than the corresponding first-dimension column throughout the programme.

The analytical method used allows for combined targeted and untargeted analysis, where a selected subset of metabolites can be quantified. In the present study, quantification of 23 target metabolites (stearic acid, oleic acid, linoleic acid, palmitic acid, citric acid, glutamic acid, 3,4-dihydroxybutyric acid, 3-hydroxybutan-2-one, 3-hydroxybutyric acid, acetoacetate, acetoacetic acid, threonine, phenylalanine, serine, lactic acid, methionine, glycine, isoleucine, leucine, valine, proline, 2-hydroxybutyric acid, cholesterol, arachidonic acid and alanine) was done by external calibration curves for each individual metabolite.

ChromATOF vendor software (LECO) was used for within-sample data processing, and the Guineu software (https://code.google.com/p/guineu/) was used for alignment, normalisation and peak matching across samples. The normalisation was performed by correction for internal standards and specific target metabolites were additionally quantified using external calibration curves. Other mass spectra from the GC × GC-TOFMS analysis were searched against the NIST 14 Mass Spectral Library and the MolMeth Database, using also retention index data in the identification. Artefact peaks due to chemical background and compounds outside the linear range of the method were removed from the dataset. Control serum samples (n = 32 for human) and pure standards (to monitor the instrument performance and robustness) were analysed together with the samples. The relative standard deviation (RSD) for internal standards, spiked into the samples, was on average of 15.7% for the plasma samples. The RSD% of the quantified metabolites in the control serum samples (n = 32) was on average 23.4%. The RSD% was 13.3% for isooleucine, 11.2% for leucine and 24.2% for valine in control serum samples (n = 4), and for internal standards in mice serum the RSD was on average 16.6%. Neither sample preparation nor analysis order showed any significant effect on the results.

All plasma metabolite peaks that were present (non-zero value) in more than 75% of samples were included in the data analyses, including the unidentified ones. The unidentified peaks were annotated with their structural class from the Golm Metabolome Database using functional group prediction based on the fragmentation patterns.21,22

Targeted metabolomic analysis
A targeted metabolomic approach was taken to target a specific metabolic pathway, that is, the tricarboxylic acid (TCA) cycle (citric acid, succinic acid, fumaric acid, malic acid, α-ketoglutaric acid). A subset of control samples at both ages 11 and 18 were used for the analysis. This resulted in the following study numbers: PD at age 11 (38 controls vs 38 cases) and PD at age 18 (36 controls vs 36 cases) (Supplementary Table 4). Briefly, 50 μl of a 0.1 mg ml $^{-1}$ mixture of labelled internal standards (succinic acid-2,2,3,3-d$_4$, fumaric acid-2,3-d$_2$, adipic acid-2,2,5,5-d$_4$, and α-malic acid-2,3,3-d$_4$, Sigma Aldrich) were added to 100 μl of plasma. To this, 440 μl of anhydrous EtOH, 100 μl of pyridine, 500 μl of deionised H$_2$O and 150 μl of ethylchlorofomate (ECF) was added and samples were vortexed. To this, 1000 μl of CHCl$_3$ was added. The pH was then adjusted to 5–6 by adding 7% NaOH solution and shaken for 5 s. Overall, 100 μl of ECF was added and vortexed for 20 s. To this, 2 ml of deionised H$_2$O was added and vortexed. The samples were then centrifuged at 1700 g for 3 min at 4 °C. The CHCl$_3$ layer was transferred to a 10 ml glass tube containing anhydrous sodium sulphate drying reagent. Following drying, samples were analysed using an Agilent 72200 Q-TOF GC/MS system (Agilent, Santa Clara, CA, USA).

Calibration was achieved by comparison of metabolite peak areas with reference to an external standard (TCA cycle metabolite library, Sigma Aldrich) and by comparison of their mass spectra with those in the NIST library (version 2.0). For quality control purposes, an aliquot from a pool of plasma was extracted and analysed in parallel with each batch of samples. Quantification of the TCA metabolites was carried out using the MassHunter TOF quantitative analysis software (version B.07.01, Agilent).

Statistical analyses
Censored regression analysis (SAS, version 9.3, Cary, NC, USA) was applied to the datasets to identify significant differences (P < 0.05) in lipid and metabolite levels between the control and PD groups at both age groups, adjusting for gender and BMI. Significant lipids and metabolites were corrected for multiple comparisons using the Benjamini–Hochberg step-up procedure in R (version 3.2.2) (P < 0.1). Censored regression analysis was applied as the majority of lipids and metabolite levels were not normally distributed and were reported in varying concentration ranges among participants. Individual lipid levels were visualised using the beanplot algorithm implemented in R. A beanplot gives information on the mean lipid level within each group, the density of the data-point distribution and illustrates individual data points.11 Cluster analysis was performed using the Mclust package44 in R (version 3.2.2), which uses Gaussian mixture modelling fitted via the expectation-maximisation (EM) algorithm for model-based clustering. Prior to clustering, the data were normalised using a logarithmic transformation.

For the targeted metabolomic analysis, metabolite levels between groups were compared using general linear models gender and BMI as covariates (SPSS version 20, IBM, Armonk, NY, USA).
The levels of the lipids in the PD case group were analysed relative to the control group as a function of the acyl chain length and double bond content within each lipid group. The level ratio was shown on the y-axis of two lipid figures, with one figure showing the number ratio and another with the number of carbon double bonds. The lipid cluster LC4 was significantly higher in the PD group. An upward sloping relationship was seen in the mean ratio of SM levels in cases vs controls for higher carbon numbers. Clear patterns are not seen for the PCs and TGs, although the figure does highlight that the PCs are elevated in the PD group and TGs are downregulated, particularly so for those with a lower number of carbon double bonds.

The global lipidome was then evaluated by clustering the data into a set of lipid clusters. Cluster analysis identified seven lipid clusters (LC) and a description of each cluster is given in Table 3. Three of the identified clusters were significantly higher in the PD case group. LC4 was dominated by LPCs (P-value = 0.025), LC6 was dominated by both PCs and CEs (P-value = 0.036), whereas LC7 was a cluster containing PCs (P-value = 0.006).

At age 18, a total of 23 lipids were significantly different between the control and PD groups (Table 4; nominal P-value < 0.05). These lipids were three LPCs, thirteen PCs, one PE, three SMs and three TGs. All of these lipids, with the exception of PC (36:4), were decreased in the PD group (Figure 2), although no clear pattern with respect to the acyl carbon chain length or double bond content was observed. The lipid cluster LC4 was significantly decreased in the PD group (P-value = 0.017) and was dominated by LPCs (Supplementary Table 1). None of these however passed significance at the selected FDR threshold of 0.1.

### RESULTS

The final lipidomic datasets used for analysis included a total of 179 lipids from the following lipid classes: cholesterol esters (CEs), lysophosphatidylcholines (LPCs), phosphatidylcholines (PCs), phosphatidylethanolamines (PEs), sphingomyelins (SMs), triglycerides (TGs), a diacylglycerol (DG) and a phosphatidylinositol (PI).

#### Age 11 and 18 lipidomic signatures of PD

At age 11, a total of 32 lipids were significantly altered between controls and cases (nominal P-value < 0.05). These lipids included three CEs, five LPCs, 19 PCs, four SM and a TG (Table 2). All of these lipids, with the exception of TG(56:7), were elevated in the PD group. Eight of these passed FDR significance (P-value < 0.1) (Figure 1). Relationships with the acyl chain length of lipid species was examined (Figures 2 and 3; Supplementary Figure 1). LPCs of lower carbon numbers and double bond content were higher in the PD group. An upward sloping relationship was seen in the mean ratio of SM levels in cases vs controls for higher carbon numbers. Clear patterns are not seen for the PCs and TGs, although the figure does highlight that the PCs are elevated in the PD group and TGs are downregulated, particularly so for those with a lower number of carbon double bonds.

The global lipidome was then evaluated by clustering the data into a set of lipid clusters. Cluster analysis identified seven lipid clusters (LC) and a description of each cluster is given in Table 3. Three of the identified clusters were significantly higher in the PD case group. LC4 was dominated by LPCs (P-value = 0.025), LC6 was dominated by both PCs and CEs (P-value = 0.036), whereas LC7 was a cluster containing PCs (P-value = 0.006).

At age 18, a total of 23 lipids were significantly different between the control and PD groups (Table 4; nominal P-value < 0.05). These lipids were three LPCs, thirteen PCs, one PE, three SMs and three TGs. All of these lipids, with the exception of PC (36:4), were decreased in the PD group (Figure 2), although no clear pattern with respect to the acyl carbon chain length or double bond content was observed. The lipid cluster LC4 was significantly decreased in the PD group (P-value = 0.017) and was dominated by LPCs (Supplementary Table 1). None of these however passed significance at the selected FDR threshold of 0.1.
Figure 1. The levels of significant lipids at FDR level for age 11 samples.

Figure 2. The relationship between psychotic disorder and acyl chain content in lipid species. The mean ratio of lipid levels in cases vs controls in plasma samples (ages 11 and 18) for lysophosphatidylcholines (LPCs).
in the PD group (Table 5), although none were significant at the selected FDR threshold. Cluster analysis identified six metabolite clusters (CL), none of which were significant between study groups (Supplementary Table 2).

At the age of 18, a total of 19 metabolites were significantly different between the case and control groups, none at FDR level (Table 6). These metabolites mainly belonged to the following classes of metabolites; organic acids, fatty acids and sugar/sugar derivatives and were all significantly decreased in the PD group with the exception of glycine and levoglucosan which were elevated in the PD group. 1-Monopalmitin is the only common significant metabolite between the studies and was found to be decreased in PD groups at both ages. The metabolite cluster CL1 was significantly decreased in the PD group (P-value = 0.034) and contained 22 metabolites consisting of fatty acids, organic acids and unknown metabolites (Supplementary Table 3).

Targeted analysis of the TCA cycle metabolites revealed no significant difference between the study groups at the ages of 11 and 18. At the age of 18, succinic acid was significantly decreased in the PD group (P-value = 0.04) (Table 7).

**DISCUSSION**

Our findings indicate that the lipidome is altered between subjects with PD compared to subjects who do not experience any PEs, particularly at the age of 11, giving promise to the potential of an early biomarker signature of PD. At the age of 11, a number of LPCs were found to be significantly elevated in the PD group. This is indicative of altered phospholipid metabolism, which has been considered as the pathophysiological basis of schizophrenia for some time. A number of studies have reported impaired phospholipid levels in schizophrenia subjects, although the specific results have not been consistent.

LPC, an inflammatory phospholipid generated by hydrolysis of PC via the actions of phospholipase A2 (PLA2), promotes inflammatory effects such as expression of endothelial cell adhesion molecules, growth factors, chemotaxis and activation of monocytes/macrophages. LPC has been suggested to have a functional role in the pathogenesis of various diseases including atherosclerosis, diabetes and systemic autoimmune diseases. The association between inflammatory abnormalities and PD has been found repeatedly in many studies, which reported increased levels of pro-inflammatory compounds (mainly cytokines) in the serum, plasma and cerebrospinal fluid of patients with psychosis or who transition to schizophrenia from the at-risk mental state. In support of the inflammatory theory in relation to psychotic outcome in the ALSPAC cohort, Khandaker et al. reported higher levels of the systemic inflammatory

---

**Table 3.** Description of lipid clusters obtained from lipidomics platform in the age 11 cohort and evaluated across the study groups

| Cluster name | Cluster size | Cluster description | P-value (controls vs cases) |
|--------------|--------------|---------------------|-----------------------------|
| LC1          | 12           | TGs                 | 0.255                       |
| LC2          | 44           | TGs                 | 0.966                       |
| LC3          | 8            | LPCs                | 0.025                       |
| LC4          | 29           | PCs and TGs         | 0.96                        |
| LC5          | 23           | PCs and SM          | 0.054                       |
| LC6          | 40           | PCs and CEs         | 0.036                       |
| LC7          | 20           | PCs                 | 0.006                       |

Abbreviations: CEs, cholesterol esters; LC, lipid cluster; LPCs, lysophosphatidylcholines; PCs, phosphatidylcholines; SM, sphingomyelins; TGs, triacylglycerols. Values in bold are lipid clusters (LC) that are significant between controls vs cases (P < 0.05).

---

Figure 3. The relationship between psychotic disorder and acyl chain content in sphingomyelins (SMs). The mean ratio of lipid levels in cases vs controls in plasma samples (ages 11 and 18) for SMs.
bonds are associated with risk of PD. An earlier study suggests that LPCs with lower carbon numbers and fewer double bonds are associated with risk of PD. A recent study reported diminished levels of LPCs (16:0, 18:0, 18:1 and 18:2) in the serum of schizophrenia patients as compared to healthy controls.12 Of the reported significant LPCs, two were also significantly elevated in this study at the age of 11 (LPC 18:1 and LPC 18:2), which suggests that LPCs with lower carbon numbers and fewer double bonds are associated with risk of PD. An earlier study reported increased platelet membrane LPC in schizophrenia patients.32 However, there are inconsistencies in studies, with one study reporting diminished levels of LPCs in the serum of schizophrenia patients compared to their co-twins as well as healthy controls.11 Furthermore, there are some noteworthy differences between this study and previous ones, particularly relating to the age of the subjects and the diagnosis. The samples studied in the current investigation were donated from participants at the ages 11 and 18 and were thus very different in terms of medication exposure and duration of psychotic illness from those of first episode or chronic schizophrenia. In comparison, the mean age of first-episode schizophrenia patients in the study by Cai and colleagues was 27.5 ± 9.5 years (n = 11). In the twin study, which involved twin pairs discordant for schizophrenia, the participants had an average age of 51 years (n = 19), with the majority taking antipsychotic medication. The differences between these studies could explain some of the inconsistencies in the reported findings related to the direction of the LPCs and also highlights the need for validation studies for biomarker confirmation. Identification of the biomarkers at a young age prior to conversion to schizophrenia would be of more benefit clinically to assist early detection and diagnosis.7

Table 4. Differential plasma lipids between control and PD groups at age 11 and 18

| Lipid name      | Control (n = 117) | Cases (n = 36) | P-value | FDR-adjusted |
|-----------------|------------------|---------------|---------|--------------|
| LPC(16:0)       | 848.58 ± 191.96  | 771.44 ± 227.83 | 0.0402 | 0.4042       |
| LPC(16:1)       | 37.75 ± 6.43     | 35.03 ± 5.67   | 0.0319 | 0.3609       |
| LPC(22:6)       | 28.63 ± 4.66     | 25.7 ± 4.46    | 0.0255 | 0.4196       |
| PC(31:0)        | 26.39 ± 7.66     | 22.9 ± 7.38    | 0.0136 | 0.4103       |
| PC(32:1)        | 281.87 ± 137.89  | 249.65 ± 106.1 | 0.0311 | 0.3752       |
| PC(33:1)        | 62.63 ± 18.43    | 54.06 ± 13.57  | 0.0007 | 0.2232       |
| PC(35:1)        | 75.59 ± 21.09    | 68.31 ± 13.57  | 0.0405 | 0.3858       |
| PC(36:2)        | 67.41 ± 21.45    | 62.37 ± 16.45  | 0.0468 | 0.3858       |
| PC(36:4)        | 2641.06 ± 637.15 | 2656.62 ± 708.18 | 0.0369 | 0.3929       |
| PC(37:4)        | 67.93 ± 26.92    | 59.57 ± 28.94  | 0.0456 | 0.4127       |
| PC(38:6)        | 114.34 ± 42.33   | 109.33 ± 32.87 | 0.0122 | 0.4416       |
| PE(18:0/22:6)   | 35.6 ± 8.05      | 32.61 ± 7.62   | 0.0466 | 0.4016       |
| PE(31:0)        | 281.87 ± 137.89  | 249.65 ± 106.1 | 0.0311 | 0.3752       |
| PE(33:1)        | 1901.22 ± 547.7  | 1783.34 ± 498.81 | 0.0259 | 0.3907       |
| PE(33:1)        | 1227.82 ± 311.1  | 1118.09 ± 297.23 | 0.003  | 0.2715       |
| PC(40:7)        | 76.27 ± 23.89    | 68.99 ± 23.89  | 0.0147 | 0.3801       |
| PC(40:7)        | 100.79 ± 36.03   | 85.19 ± 33.38  | 0.0213 | 0.4283       |
| PC(40:6)        | 34.75 ± 6.81     | 32.08 ± 6.39   | 0.0169 | 0.3823       |
| PC(42:3)        | 29.63 ± 6.56     | 26.94 ± 7.07   | 0.047  | 0.3699       |
| SM(18:0/16:0)   | 890.9 ± 207.12   | 850.9 ± 189.57 | 0.0118 | 0.534        |
| SM(32:1)        | 1901.22 ± 547.7  | 1783.34 ± 498.81 | 0.0259 | 0.3907       |
| SM(33:1)        | 1227.82 ± 311.1  | 1118.09 ± 297.23 | 0.003  | 0.2715       |
| TG(49:3)        | 33.78 ± 1.18     | 33.31 ± 1.53   | 0.0242 | 0.438        |
| TG(51:2)        | 26.14 ± 3.26     | 24.06 ± 5.41   | 0.0024 | 0.4344       |
| TG(56:7)        | 106.1 ± 58.84    | 95.83 ± 76.34  | 0.0288 | 0.401        |

Table 5. Differential plasma metabolites between control and PD groups at age 11

| Metabolite name          | Control (n = 67) | Cases (n = 38) | P-value | FDR-adjusted |
|--------------------------|------------------|---------------|---------|--------------|
| 1-monopalmitin           | 448.89 ± 162     | 363.91 ± 123.4 | 0.0128 | 0.544        |
| 2,4-Dihydroxybutanoic acid | 0.09 ± 0.03    | 0.07 ± 0.02   | 0.014  | 0.544        |
| D-(-)-ribofuranose       | 98.34 ± 169.78   | 52.87 ± 40.02 | 0.0429 | 0.7          |
| Ethanolamine             | 250.51 ± 88.88   | 214.15 ± 46.75 | 0.0215 | 0.544        |
| Ribitol                  | 175.9 ± 41.79    | 155.67 ± 31.77 | 0.0202 | 0.544        |
| Hydroxylamine            | 88.11 ± 38.61    | 66.69 ± 39.02  | 0.0043 | 0.544        |
| Sugar derivative         | 805.27 ± 247.15  | 961.92 ± 337.63 | 0.0027 | 0.591        |
| D-(-)-ribofuranose       | 89.91 ± 74.69    | 141.94 ± 85.59 | 0.0216 | 0.544        |

Abbreviations: CE, cholesterol ester; LPC, lysophosphatidylcholine; PC, phosphatidylcholine; PD, psychotic disorder; SM, sphingomyelin; TG, triacylglycerol. Values are expressed as standard units ± s.d. (standard deviation). P-values are adjusted for gender and BMI. FDR-adjusted P-values are adjusted for multiple comparisons using the Benjamini–Hochberg procedure.
that biomarker profiles may change with age. Furthermore, it suggests that the pathophysiological process can alter over time and with proximity to disease onset. A similar finding was reported in type 1 diabetes where increased LPCs were identified in children who later progressed to the disease. Following early seroconversion to autoantibody positivity, the metabolic profiles of the participants were partially normalised, indicating that lipidomic approaches are involved in aetiological pathways and are subsequently likely to be decreased in the PD group at both ages and is a lipid storage source. Citric acid and succinic acid (targeted metabolomics analyses) were found to be reduced in the PD group at age 11 and 18, and with proximity to disease onset. A major strength of this investigation is the ALSPAC cohort upon which it was based. The ALSPAC cohort includes detailed longitudinal clinical assessments and biosampling. The plasma samples were collected at age 11, prior to the development of psychotic disorder, and were not subject to confounds of drug exposure and chronic illness. Our observation of an altered lipidome at age 11, therefore, highlights a perturbed metabolism related to inflammation in the PD group, which may be an early biomarker signature of the disease, with the LPCs representing potential future early biomarkers of PD. The detected associations indicate that lipidomic profiles are useful for identifying important disease signatures. However, as a step to move these signatures closer to utilisation in the clinic validation in an external cohort is necessary. Notwithstanding this, the present study is an important step towards the identification of a signature associated with the development of PD.

**CONFLICT OF INTEREST**

The authors declare no conflict of interest.

**ACKNOWLEDGMENTS**

We are extremely grateful to all the families who took part in this study, the midwives for their help in recruiting them, and the whole ALSPAC team, which includes interviewers, computer and laboratory technicians, clerical workers, research scientists, volunteers, managers, receptionists and nurses. The UK Medical Research Council and Wellcome (Grant Ref: 102215/2/13/2) and the University of Bristol provide core support for ALSPAC. This study is also supported by the NIHR Bristol BRC. This research was specifically funded by the Irish Health Research Board through a Clinician Scientist Award to DRC. This project was funded by the Health Research Board (ref HRA-POR-2013-282; HBR CSA 2012/8). LB is supported by a European Research Council grant (ERC (647783)). We thank Anette Untermann at Steno Diabetes Center A/S for preparing all samples for the lipidomics analyses and for the fruitful discussions. The authors declare no conflict of interest.

**DISCLAIMER**

This publication is the work of the authors and will serve as guarantors for the contents of this paper.
REFERENCES
1. Ustun TB. The global burden of mental disorders. Am J Public Health 1999; 89: 1315–1318.
2. van Os J, Kapur S. Schizophrenia. Lancet 2009; 374: 635–645.
3. Fusar-Poli P, Bonoldi I, Yang AR, Borgwardt S, Kempton MJ, Valmaggia L et al. Predicting psychosis: meta-analysis of transition outcomes in individuals at high clinical risk. Arch Gen Psychiatry 2012; 69: 220–229.
4. Larsen TK, Melle I, Auestad B, Haahr U, Joa I, Johannessen JO et al. Early detection of psychosis: positive effects on 5-year outcome. Psychol Med 2011; 41: 1461–1469.
5. Addington J, Cornblatt BA, Cadenhead KS, Cannon TD, McCloughan TH, Perkins DO et al. At clinical high risk for psychosis: outcome for nonconverters. Am J Psychiatry 2011; 168: 800–805.
6. Sawa A, Snyder SH. Schizophrenia: diverse approaches to a complex disease. Science 2002; 296: 692–695.
7. Oresic M, Tang J, Seppanen-Laasko T, Mattila I, Saarini SE, Saarini SI et al. Metabolome in schizophrenia and other psychiatric disorders: a general population-based study. Genome Med 2011; 3: 19.
8. Yang J, Chen T, Sun L, Zhao Z, Qi X, Zhou K et al. Potential metabolite markers of schizophrenia. Mol Psychiatry 2013; 18: 67–78.
9. Holmes E, Tsang TM, Huang JT, Leweke FM, Koethe D, Gerth CW et al. Metabolic profiling of CSF: evidence that early intervention may impact on disease progression and outcome in schizophrenia. PLoS Med 2006; 3: e327.
10. Schwarz E, Prabakaran S, Whitfield P, Major H, Leweke FM, Koethe D et al. High throughput lipidomic profiling of schizophrenia and bipolar disorder brain tissue reveals alterations of free fatty acids, phosphatidylcholines, and ceramides. J Proteome Res 2008; 7: 4266–4277.
11. Oresic M, Seppanen-Laasko T, Sun D, Tang J, Therman S, Viehman R et al. Phospholipids and insulin resistance in psychosis: a lipidomics study of twin pairs discordant for schizophrenia. Genome Med 2012; 4: 1.
12. Cai HL, Li HD, Yan XZ, Sun B, Zhang Q, Yan M et al. Metabolomic analysis of biochemical changes in the plasma and urine of first episode neuroleptic-naive schizophrenia patients after treatment with risperidone. J Proteome Res 2012; 11: 4338–4350.
13. Khan MM, Evans DR, Gunna V, Scheffer RE, Parikh VW, Madahip SP. Reduced erythrocyte membrane essential fatty acids and increased lipid peroxides in schizophrenia at the never-medicated first-episode of psychosis and after years of treatment with antipsychotics. Schizophr Res 2002; 58: 1–10.
14. Prabakaran S, Watton JE, Ryan MM, Hufskaf SJ, Huang JT, Griffin JL et al. Mitochondrial dysfunction in schizophrenia: evidence for compromised brain metabolism and oxidative stress. Mol Psychiatry 2004; 9: 684–697, 643.
15. Yao JK, Dougherty GG Jr, Reddy RD, Keshavam S, Montrose DM, Matson WR et al. Altered interactions of tryptophan metabolites in first-episode neuroleptic-naive patients with schizophrenia. Mol Psychiatry 2010; 15: 938–953.
16. Xuan J, Pan G, Qiu Y, Wang L, Su M, Liu Y et al. Metabolomic profiling to identify potential serum biomarkers for schizophrenia and risperidone action. J Proteome Res 2011; 10: 5433–5443.
17. Money TT, Bousman CA. Metabolomics of psychiatric disorders. Metabolomics 2013; 3: 117.
18. Rice SM, Schafer MR, Klier C, Mosaheb N, Vijayakumar N, Amminger GP. Erythrocyte polyunsaturated fatty acid levels in young people at ultra-high risk for psychotic disorder and healthy adolescent controls. Psychiatry Res 2015; 228: 174–176.
19. Boyd A, Golding J, Macleod J, Lawlor DA, Fraser A, Henderson J et al. Cohort Profile: the ‘children of the 90s’—the index offspring of the Avon Longitudinal Study of Parents and Children. Int J Epidemiol 2013; 42: 111–127.
20. Zammit S, Kounali D, Cannon M, David AS, Gunnell D, Heron J et al. Psychotic experiences and psychotic disorders at age 18 in relation to psychotic experiences at age 12 in a longitudinal population-based cohort study. Am J Psychiatry 2003; 160: 742–750.
21. Folch J, Lees M, Sloane Stanley GH. A simple method for the isolation and purification of total lipides from animal tissues. J Biol Chem 1957; 226: 497–509.
22. Castillo S, Mattila I, Miettinen J, Oresic M, Hyotylainen T. Data analysis tool for comprehensive two-dimensional gas chromatography/time-of-flight mass spectrometry. Anal Chem 2011; 83: 3058–3067.
23. Kopka J, Schauer N, Krueger S, Birkemeyer C, Usadel B, Bergmuller E et al. GMDjDepCSB.DB: the Gobol Metabolome Database. Bioinformatics 2005; 21: 1635–1638.
24. Fraley C, Raftery AE. Model-based methods of classification: using the mclust software in chemometrics. J Stat Softw 2007; 18: 1–13.
25. Kita T, Kume N, Ishi K, Horiiuchi H, Arai H, Yokode M. Oxidized LDL and expression of monocyte adhesion molecules. Diabet Res Clin Pract 1999; 45: 123–126.
26. Lusis AJ. Atherosclerosis. Nature 2000; 407: 233–241.
27. Shi AH, Yoshinari M, Wakisaka M, Iwase M, Fujishima M. Lysophosphatidylcholine molecular species in low density lipoprotein of type 2 diabetes. Horm Metab Res 1999; 31: 283–286.
28. Wu R, Svennungsson E, Gunnarsson I, Andersson B, Lundberg I, Schafer Elinder L et al. Antibodies against lysophosphatidylcholin and oxidized LDL in patients with SLE. Lupus 1999; 8: 142–150.
29. Bergink V, Gibney SM, Drexhage HA. Autoimmunity, inflammation, and psychosis: a search for peripheral markers. Biol Psychiatry 2014; 75: 324–331.
30. Focking M, Dicker P, Lopez LM, Cannon M, Schafer MR, McGorry PD et al. Differential expression of the inflammation marker IL12p40 in the at-risk mental state for psychosis: a predictor of transition to psychotic disorder? BMC Psychiatry 2016; 16: 326.
31. Khandaker GM, Pearson RM, Zammit S, Lewis G, Jones PB. Association of serum interleukin 6 and C-reactive protein in childhood with depression and psychosis in young adult life a population-based longitudinal study. JAMA Psychiatry 2014; 71: 1121–1128.
32. Pangerl AM, Steudle A, Jaroni HW, Rufer R, Gattaz W. Increased platelet membrane lysophosphatidylcholine in schizophrenia. Biol Psychiatry 1991; 30: 837–840.
33. Ryazantseva NV, Novitskii VV, Kubinskaya MM. Changes in the lipid phase of erythrocyte membranes in patients with paranoid schizophrenia. Bull Exp Biol Med 2002; 133: 84–86.
34. Kaddurah-Daouk R, McEvoy J, Bousman CA, Money TT, Gibbons A, Dean B et al. Impaired plasmalogens in patients with schizophrenia. Psychiatry Res 2012; 198: 347–352.
35. Courvoisie H, Labellarte MJ, Riddle MA. Psychosis in children: diagnosis and treatment. Dialogues Clin Neurosci 2001; 3: 79–92.
36. Oresic M, Simell S, Syssi-Aho M, Nanto-Salonen K, Seppanen-Laasko T, Parikka V et al. Dysregulation of lipids and amino acid metabolism precedes islet autoimmunity in children who later progress to type 1 diabetes. J Exp Med 2008; 205: 2975–2984.
37. Chana G, Bousman CA, Money TT, Gibbons A, Gillett P, Dean B et al. Biomarker investigations related to pathophysiological pathways in schizophrenia and psychosis. Front Cell Neurosci 2013; 7: 95.
38. Motssinger-Reif AA, Zhu H, Kling MA, Matson W, Sharma S, Fiehn O et al. Comparing metabolomic and pathologic biomarkers alone and in combination for discriminating Alzheimer’s disease from normal cognitive aging. Acta Neuropathol Commun 2013; 1: 28.
39. Pennington K, Beasley CL, Dicker P, Fagan A, English J, Pariente CM et al. Prominent synaptic and metabolic abnormalities revealed by proteomic analysis of the dorsolateral prefrontal cortex in schizophrenia and bipolar disorder. Mol Psychiatry 2008; 13: 1102–1117.
40. Focking M, Lopez LM, English JA, Dicker P, Wolff A, Brindley E et al. Proteomic and genomic evidence implicates the postsynaptic density in schizophrenia. Mol Psychiatry 2015; 20: 424–432.
41. English JA, Pennington K, Dunn MJ, Cotter DR. The neuroproteomics of schizophrenia. Biol Psychiatry 2011; 69: 163–172.

Supplementary Information accompanies the paper on the Translational Psychiatry website (http://www.nature.com/tp)